Roche acquires Tensha Therapeutics and with it TEN 010 cancer treatment

Tensha Therapeutics, a privately-held company based in Cambridge, USA, announced it will be acquired by Roche. Founded by James E. Bradner, MD, formerly of the Dana-Farber Cancer Institute, and managed and funded by HealthCare Ventures, Tensha has developed a pioneering epigenetic technology that disrupts bromodomain and extra terminal domain (BET) proteins in order to develop potential treatments for cancer. The lead product, TEN-010, is a small molecule BET inhibitor that is currently in two Phase 1b clinical trials for the treatment of patients with cancer. The transaction is anticipated to close in the first quarter of 2016.